Na-Phenylbutyrate VAscular Trial

Starting soon · Early Phase 1 · Has a placebo group

Conditions studied: Diabetes

In brief

This study will investigate if the drug sodium phenylbutyrate (NaPB) impacts blood pressure and vascular function in healthy volunteers and in patients with diabetes.

Key facts

Study ID

NCT06645769

Run by

University of Pennsylvania

People needed

30

Starts

2027-06-01

Expected to finish

2029-06-01

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Over 18 years of age and less than 60.
• Healthy subjects will have no history of diabetes or prediabetes.
• Diabetes subjects can be either insulin dependent or not.
• Able to provide written consent and to comply with the procedures of the study protocol.

You may not qualify if…

• Age <18 or >60
• Pregnant or lactating women.
• Subjects with hypertension or taking any vasodilatory medications, any steroidal drugs, haloperidol, or valproic acid.
• Patients with congestive heart failure, severe renal insufficiency, hepatic failure, or known sodium retention with oedema.
• Active alcohol or substance abuse.
• Use of tobacco within the previous six months.
• Unble to provide written consent and to comply with the procedures of the study protocol.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.